Original ArticleA randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Under a Creative Commons license
open access
Key words
bone metastases
mCRPC
radium-223 dose
safety
symptomatic skeletal events
Cited by (0)
© 2019 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.